KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

AbCellera Biologics (ABCL) Depreciation Expense: 2022-2023

Historic Depreciation Expense for AbCellera Biologics (ABCL) over the last 2 years, with Dec 2023 value amounting to $3.9 million.

  • AbCellera Biologics' Depreciation Expense rose 39.89% to $3.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $12.9 million, marking a year-over-year increase of 43.52%. This contributed to the annual value of $12.5 million for FY2024, which is 2.05% down from last year.
  • AbCellera Biologics' Depreciation Expense amounted to $3.9 million in Q4 2023, which was up 25.81% from $3.1 million recorded in Q3 2023.
  • AbCellera Biologics' 5-year Depreciation Expense high stood at $3.9 million for Q4 2023, and its period low was $1.4 million during Q1 2022.
  • In the last 2 years, AbCellera Biologics' Depreciation Expense had a median value of $2.8 million in 2022 and averaged $2.7 million.
  • Data for AbCellera Biologics' Depreciation Expense shows a peak YoY surged of 107.14% (in 2023) over the last 5 years.
  • Over the past 2 years, AbCellera Biologics' Depreciation Expense (Quarterly) stood at $2.8 million in 2022, then skyrocketed by 39.89% to $3.9 million in 2023.
  • Its Depreciation Expense was $3.9 million in Q4 2023, compared to $3.1 million in Q3 2023 and $3.0 million in Q2 2023.